[HTML] frontiersin.org

[HTML][HTML] Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado… - Frontiers in …, 2023 - frontiersin.org
Lymphodepletion (LD) or conditioning is an essential step in the application of currently
used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it …
被引用次数：20 相关文章

[引用][C] Lymphodepletion-an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado… - … in Immunology (Web), 2023 - jglobal.jst.go.jp
Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of
cancer with tumor-infiltrating lymphocytes. Science (1986) 233 (4770): 1318-21. doi: doi …
[HTML] nih.gov

[HTML][HTML] Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Lymphodepletion (LD) or conditioning is an essential step in the application of currently
used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it …
[PDF] umcutrecht.nl

[PDF][PDF] Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado… - 2023 - researchinformation.umcutrecht.nl
Background Adoptive cell transfer (ACT) for the treatment of malignancies has become one
of the most active and fruitful developments in therapeutic advances against cancer in the …

Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado… - Frontiers in …, 2023 - europepmc.org
Lymphodepletion (LD) or conditioning is an essential step in the application of currently
used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it …
[PDF] researchgate.net

[PDF][PDF] Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado, L Warmuth… - 2023 - researchgate.net
Background Adoptive cell transfer (ACT) for the treatment of malignancies has become one
of the most active and fruitful developments in therapeutic advances against cancer in the …

Lymphodepletion-an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Lymphodepletion (LD) or conditioning is an essential step in the application of currently
used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it …
[PDF] semanticscholar.org

[PDF][PDF] Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado, L Warmuth… - 2023 - pdfs.semanticscholar.org
Background Adoptive cell transfer (ACT) for the treatment of malignancies has become one
of the most active and fruitful developments in therapeutic advances against cancer in the …
[PDF] researchgate.net

[PDF][PDF] Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

B Lickefett, L Chu, V Ortiz-Maldonado, L Warmuth… - 2023 - researchgate.net
Background Adoptive cell transfer (ACT) for the treatment of malignancies has become one
of the most active and fruitful developments in therapeutic advances against cancer in the …

Lymphodepletion-an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.

B Lickefett, L Chu, V Ortiz-Maldonado… - Frontiers in …, 2023 - europepmc.org
Lymphodepletion (LD) or conditioning is an essential step in the application of currently
used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it …